Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
Diallo A, Victor JC, Feser J, Ortiz JR, Kanesa-Thasan N, Ndiaye M, Diarra B, Cheikh S, Diene D, Ndiaye T, Ndiaye A, Lafond KE, Widdowson MA, Neuzil KM. Diallo A, et al. Among authors: kanesa thasan n. Vaccine. 2018 Oct 15;36(43):6424-6432. doi: 10.1016/j.vaccine.2018.08.032. Epub 2018 Sep 14. Vaccine. 2018. PMID: 30224199 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine.
Pierson BC, Cardile AP, Okwesili AC, Downs IL, Reisler RB, Boudreau EF, Kortepeter MG, Koca CD, Ranadive MV, Petitt PL, Kanesa-Thasan N, Rivard RG, Liggett DL, Haller JM, Norris SL, Purcell BK, Pittman PR, Saunders DL, Keshtkar Jahromi M. Pierson BC, et al. Among authors: kanesa thasan n. Vaccine. 2021 May 12;39(20):2780-2790. doi: 10.1016/j.vaccine.2021.03.030. Epub 2021 Apr 19. Vaccine. 2021. PMID: 33888325 Free article.
Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P, Anderson E, Kerdpanich P, Bulitta M, Kanesa-Thasan N, Hohenboken M. Chanthavanich P, et al. Among authors: kanesa thasan n. Pediatr Infect Dis J. 2019 Jul;38(7):757-764. doi: 10.1097/INF.0000000000002345. Pediatr Infect Dis J. 2019. PMID: 31194712 Clinical Trial.
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garçon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL. Robert Putnak J, et al. Vaccine. 2005 Aug 15;23(35):4442-52. doi: 10.1016/j.vaccine.2005.03.042. Vaccine. 2005. PMID: 16005749
Recombination and flavivirus vaccines: a commentary.
Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, Quentin-Millet MJ, Barrett AD, Brinton MA, Cetron MS, Barwick RS, Chambers TJ, Halstead SB, Roehrig JT, Kinney RM, Rico-Hesse R, Strauss JH. Monath TP, et al. Vaccine. 2005 Apr 27;23(23):2956-8. doi: 10.1016/j.vaccine.2004.11.069. Vaccine. 2005. PMID: 15811640 No abstract available.
47 results